NEW APPROACHES TO BRAIN TUMOR THERAPY CNS CONSORTIUM

这项建议的主要长期目标是改善 成人原发性脑肿瘤的治疗结果。这将是 通过促进Promising的I期和II期临床评估完成 新的药物、生物方法和给药途径 中枢神经系统(CNS)原发性恶性肿瘤的治疗 通过建立名为“新方法”的CNS财团 脑瘤治疗(NABTT)。这个联盟是专门设计的 结合并专注于以下七个方面的经验、资源和功能 杰出的医疗机构(约翰·霍普金斯大学，布朗 哥伦比亚大学、克利夫兰诊所、马萨诸塞州 西北大学[芝加哥]总医院和芝加哥大学 宾夕法尼亚州)对原发脑瘤负有责任。为了达到这一目标， 财团将依赖于剩下的特殊优势和能力 在每个参与机构内和在财团内作为 完整的。参与的机构有(1)大量的成年人 原发性脑肿瘤患者，(2)多学科临床专家 有适当的团队照顾这些患者；(3)广泛的临床和 实验室资源，(4)数量惊人的持续高质量， 临床相关、同行评审和NIH资助的临床和实验室 脑肿瘤研究项目，(5)国家认可的 肿瘤学、药理学、新药开发、I期和II期临床 试验、神经外科和神经病理学(6)广泛的专业知识 统计、数据管理和多机构间的协调 研究，以及(7)在临床护理方面的卓越声誉 和研究。该财团通过背书增加了这些优势 章程，明确的组织结构，强调 研究设计、方案制定、质量控制、研究监测、 以及数据管理和分析。 这项提议的次要长期目标是利用这一点 财团将共享人脑肿瘤标本和其他临床标本 和实验室数据进行与(1)有关的额外研究 原发脑肿瘤的基础生物学，(2)新的神经药理学 原发脑肿瘤的治疗，以及(3)提高护理和质量 对患有原发脑瘤的成年人的生活的影响。这一目标将是 利用各机构和NABTT的优势达成协议 CNS财团，如上所述。

The primary long-term objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors. This will be accomplished by fostering Phase I and II clinical evaluations of promising new agents, biologic approaches, and routes of administration in the treatment of primary malignancies of the central nervous system (CNS) through the establishment of the CNS consortium titled "New Approaches to Brain Tumor Therapy (NABTT)." This consortium is specifically designed to combine and focus the experience, resources, and capabilities of seven outstanding medical institutions (The Johns Hopkins University, Brown University, Columbia University, The Cleveland Clinic, The Massachusetts General Hospital, Northwestern University [Chicago], and The University of Pennsylvania) to bear on primary brain tumors. To meet this objective, the consortium will rely on the special strengths and abilities that rest within each participating institution and within the consortium as a whole. The participating institutions have (1) a large number of adult patients with primary brain tumors, (2) expert multidisciplinary clinical teams in place to care for these patients, (3) extensive clinical and laboratory resources, (4) a striking number of ongoing high quality, clinically relevant, peer-reviewed and NIH funded clinical and laboratory brain tumor research projects, (5) nationally recognized expertise in oncology, pharmacology, new drug development, Phase I and II clinical trials, neurosurgery, and neuropathology (6) extensive expertise in statistics, data management, and the coordination of multi-institutional studies, and (7) exceptional reputations for excellence in clinical care and research. The consortium adds to these strengths by endorsed constitution, well-defined organizational structure, and emphasis on research design, protocol development, quality control, study monitoring, and data management and analysis. The secondary long-term objective of this proposal is to utilize this consortium to share human brain tumor specimens as well as other clinical and laboratory data to conduct additional research pertaining to (1) the basic biology of primary brain tumors, (2) the neuropharmacology of new therapies for primary brain tumors, and (3) improving the care and quality of life of adults with primary brain tumors. This objective will be reached using the strengths of the individual institutions and the NABTT CNS Consortium which are outlined above.